DYP688 Antibody-Drug Conjugate Shows Promise in GNAQ/GNA11-Mutant Melanoma Phase 1 Trial
- A phase 1 clinical trial of the antibody-drug conjugate DYP688 demonstrated acceptable safety and preliminary efficacy in patients with GNAQ/GNA11-mutant metastatic uveal melanoma and other GNAQ/GNA11-mutant melanomas, according...
- The therapy targets PMEL and delivers a Gq/11 inhibitor directly to cancer cells.
- DYP688 is designed as an antibody-drug conjugate, a type of targeted therapy that combines a monoclonal antibody with a potent cytotoxic payload.
A phase 1 clinical trial of the antibody-drug conjugate DYP688 demonstrated acceptable safety and preliminary efficacy in patients with GNAQ/GNA11-mutant metastatic uveal melanoma and other GNAQ/GNA11-mutant melanomas, according to a study published July 13, 2026, in Nature Medicine.
The therapy targets PMEL and delivers a Gq/11 inhibitor directly to cancer cells. Researchers reported that biomarker data supported the proof of mechanism for the drug, suggesting it successfully reached its intended molecular targets in the patients treated during the trial.
DYP688 Mechanism and Target in GNAQ/GNA11-Mutant Melanomas
DYP688 is designed as an antibody-drug conjugate, a type of targeted therapy that combines a monoclonal antibody with a potent cytotoxic payload. According to the Nature Medicine report, this specific conjugate targets PMEL, a protein often expressed in melanoma cells, to deliver a Gq/11 inhibitor.
The drug specifically addresses melanomas characterized by mutations in the GNAQ or GNA11 genes.
Phase 1 Trial Results and Safety Profile
Beyond safety, the study noted encouraging preliminary efficacy.
The Nature Medicine study highlighted that biomarker data provided evidence for the drug’s proof of mechanism.